Therapeutic and Sub-Therapeutic Quetiapine (Seroquel) Plasma Concentrations
For adults with schizophrenia, therapeutic quetiapine plasma concentrations range from 100-500 ng/mL, with levels below 100 ng/mL considered sub-therapeutic. However, the evidence base for quetiapine therapeutic drug monitoring (TDM) is weaker than for other antipsychotics, and disease-specific ranges may differ substantially.
Disease-Specific Therapeutic Ranges
The therapeutic range varies significantly by indication:
Schizophrenia
- Therapeutic range: 150-550 ng/mL 1
- Sub-therapeutic: <150 ng/mL
- Mean concentration in responders: 389 ± 286 ng/mL
- Response rate at therapeutic levels: 73.7%
Bipolar Mania
- Therapeutic range: 180-580 ng/mL 1
- Sub-therapeutic: <180 ng/mL
Depression
- Therapeutic range: 120-480 ng/mL 1
- Sub-therapeutic: <120 ng/mL
- Mean concentration in responders: 302 ± 276 ng/mL
- Response rate: 82.3%
- Notably requires lower concentrations than schizophrenia despite higher response rates
Insomnia (in Depression)
- Therapeutic range: 40-120 ng/mL (12-hour trough levels) 1
- Sub-therapeutic: <40 ng/mL
- Highest response rate observed: 85.7%
- This represents a dramatically lower range than other indications
Important Clinical Considerations
Wide Concentration Variability
There is marked inter-individual variability in quetiapine pharmacokinetics. The concentration-to-dose ratio varies up to 238-fold between patients 2. For doses ranging 37.5-1200 mg/day, serum concentrations ranged from undetectable (<10 nmol/L) to 999 nmol/L 2.
Orienting Range for Routine Treatment
Under routine conditions (excluding carbamazepine co-administration), 80% of patients have levels between 50-650 nmol/L (approximately 15-200 ng/mL) when dosed within recommended ranges 2.
Pediatric Populations
The adult therapeutic range does NOT apply to children and adolescents. Only 38.5% of adolescent patients had concentrations within the adult therapeutic range 3. Preliminary data suggest considerably lower ranges for minors:
A positive correlation exists between weight-adjusted dose and serum concentration in adolescents (rs = 0.580, p < 0.001) 3.
Timing of Blood Sampling
Blood samples must be drawn at trough levels (12 hours post-dose) under steady-state conditions 2. This is critical because quetiapine has a short half-life, and there is a documented discrepancy between receptor occupancy time course and plasma concentrations 4.
Drug Interactions Affecting Levels
CYP3A4 Inhibitors
Co-administration with venlafaxine (mild CYP3A4 inhibitor) significantly increases quetiapine concentrations in depression patients 1. Patients receiving drugs competing for CYP3A4 metabolism showed 70% higher median concentration-to-dose ratios (0.48 vs 0.28 nmol/L/mg/24h) 2.
CYP3A4 Inducers
Carbamazepine dramatically reduces quetiapine levels, with concentration-to-dose ratios of only 0.02-0.04 nmol/L/(mg/24h) 2. This represents a clinically significant interaction requiring dose adjustment or alternative therapy.
No Significant Interactions
Valproate and lithium co-administration did not significantly impact quetiapine concentrations 1.
Limitations of TDM for Quetiapine
The utility of therapeutic drug monitoring for quetiapine remains controversial 4. Unlike clozapine, there is limited evidence supporting a clear relationship between plasma concentrations and clinical response 4. The AGNP-TDM guidelines classify quetiapine TDM as "useful" (Level 3) rather than "strongly recommended" or "recommended" 5.
When TDM is Most Useful:
- Suspected non-adherence
- Lack of clinical response at adequate doses
- Adverse effects at therapeutic doses
- Drug interaction concerns (especially CYP3A4 inducers/inhibitors)
- Pediatric/adolescent populations
- Elderly patients (>65 years)
- Hepatic or renal insufficiency
- Forensic psychiatry settings
Safety Considerations
In elderly patients using low-dose quetiapine for insomnia, there are significant safety concerns including increased mortality (HR 3.1 vs trazodone), dementia (HR 8.1 vs trazodone, HR 7.1 vs mirtazapine), and falls (HR 2.8 vs trazodone) 6. This suggests that even at low concentrations, quetiapine carries substantial risk in vulnerable populations.
Practical Algorithm
- Measure trough levels (12 hours post-dose) at steady state (typically 5-7 days)
- Apply disease-specific ranges rather than generic adult ranges
- For schizophrenia: Target 150-550 ng/mL; levels <150 ng/mL are sub-therapeutic
- For depression: Target 120-480 ng/mL; lower than schizophrenia despite good efficacy
- For insomnia: Target 40-120 ng/mL; dramatically lower than other indications
- In adolescents: Consider 53-234 ng/mL as preliminary range; adult ranges do not apply
- Check for CYP3A4 interactions: Adjust expectations if inhibitors present; avoid inducers like carbamazepine
- Interpret cautiously: Clinical response should guide therapy more than levels alone